JP2021521103A5 - - Google Patents
Info
- Publication number
- JP2021521103A5 JP2021521103A5 JP2020554433A JP2020554433A JP2021521103A5 JP 2021521103 A5 JP2021521103 A5 JP 2021521103A5 JP 2020554433 A JP2020554433 A JP 2020554433A JP 2020554433 A JP2020554433 A JP 2020554433A JP 2021521103 A5 JP2021521103 A5 JP 2021521103A5
- Authority
- JP
- Japan
- Prior art keywords
- use disorder
- pharmaceutical composition
- pharmaceutically acceptable
- gaboxadol
- acceptable salt
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862653641P | 2018-04-06 | 2018-04-06 | |
| US62/653,641 | 2018-04-06 | ||
| US201862654786P | 2018-04-09 | 2018-04-09 | |
| US62/654,786 | 2018-04-09 | ||
| PCT/US2019/026218 WO2019195813A1 (en) | 2018-04-06 | 2019-04-06 | Use of gaboxadol in the treatment of substance use disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521103A JP2021521103A (ja) | 2021-08-26 |
| JP2021521103A5 true JP2021521103A5 (https=) | 2022-04-11 |
| JPWO2019195813A5 JPWO2019195813A5 (https=) | 2022-04-11 |
Family
ID=68101544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554433A Pending JP2021521103A (ja) | 2018-04-06 | 2019-04-06 | 物質使用障害の処置におけるガボキサドールの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190321341A1 (https=) |
| EP (1) | EP3761979A4 (https=) |
| JP (1) | JP2021521103A (https=) |
| KR (1) | KR20210039324A (https=) |
| CN (1) | CN112601524A (https=) |
| AU (1) | AU2019249277A1 (https=) |
| CA (1) | CA3095682A1 (https=) |
| IL (1) | IL277805A (https=) |
| MX (1) | MX2020010545A (https=) |
| WO (1) | WO2019195813A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
| IT1313585B1 (it) * | 1999-07-30 | 2002-09-09 | Neuroscienze S C A R L | Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. |
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| DK1641456T3 (da) * | 2003-06-25 | 2010-06-21 | Lundbeck & Co As H | Gaboxadol til behandling af depression og andre affektive lidelser |
| EP1868593A2 (en) * | 2005-04-07 | 2007-12-26 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| CN101168056A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 混合物制剂 |
| CN101168058A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 一种混合物制剂 |
| CN101168057A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 多巴胺激动剂制剂 |
| GB0810063D0 (en) * | 2008-06-03 | 2008-07-09 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| WO2011069860A1 (en) * | 2009-12-08 | 2011-06-16 | Chr. Hansen A/S | Novel use for the treatment of metabolic endotoxemia |
| MX2013002162A (es) * | 2010-08-24 | 2013-04-05 | Univ California | Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina. |
-
2019
- 2019-04-06 MX MX2020010545A patent/MX2020010545A/es unknown
- 2019-04-06 JP JP2020554433A patent/JP2021521103A/ja active Pending
- 2019-04-06 KR KR1020207032162A patent/KR20210039324A/ko not_active Withdrawn
- 2019-04-06 US US16/377,172 patent/US20190321341A1/en not_active Abandoned
- 2019-04-06 AU AU2019249277A patent/AU2019249277A1/en not_active Abandoned
- 2019-04-06 CN CN201980037011.8A patent/CN112601524A/zh active Pending
- 2019-04-06 EP EP19781960.0A patent/EP3761979A4/en not_active Withdrawn
- 2019-04-06 WO PCT/US2019/026218 patent/WO2019195813A1/en not_active Ceased
- 2019-04-06 CA CA3095682A patent/CA3095682A1/en active Pending
-
2020
- 2020-10-05 IL IL277805A patent/IL277805A/en unknown
-
2022
- 2022-04-19 US US17/723,979 patent/US20220241253A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wadgave et al. | Nicotine replacement therapy: an overview | |
| US10376657B2 (en) | Medicinal vapor filtration system | |
| Tønnesen et al. | Smoking cessation with four nicotine replacement regimes in a lung clinic | |
| JP2021521103A5 (https=) | ||
| Frishman et al. | Nicotine and non-nicotine smoking cessation pharmacotherapies | |
| JP2025081331A5 (https=) | ||
| Niaura et al. | Varenicline | |
| EP4385575A2 (en) | Composition comprising methylphenidate and ondansetron for use in substance-related disorders | |
| Wex et al. | The long‐acting β2‐adrenoceptor agonist olodaterol attenuates pulmonary inflammation | |
| McRobbie et al. | Non-nicotine pharmacotherapies for smoking cessation | |
| Frishman | Smoking cessation pharmacotherapy | |
| IL277253B2 (en) | Formulations of cyclosporine and use in the treatment of obliterative bronchiolitis syndrome | |
| US9724340B2 (en) | Antitussive compositions and methods | |
| NL2018504B1 (en) | Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction | |
| Agrawal et al. | Medical management of inpatients with tobacco dependency | |
| US20150258109A1 (en) | Low dose administration of ibogaine for treating nicotine addiction and preventing relapse of nicotine use | |
| JPWO2019195813A5 (https=) | ||
| JPWO2021050203A5 (https=) | ||
| US20020168403A1 (en) | Compositions and therapy for substance addiction | |
| US20110034442A1 (en) | Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders | |
| Sees et al. | Use of clonidine in nicotine withdrawal | |
| Lee et al. | Roles of adenosine and serotonin receptors on the antinociception of sildenafil in the spinal cord of rats | |
| Wise et al. | A review of nonpharmacologic and pharmacologic therapies for smoking cessation. | |
| JP2002532549A (ja) | ５ｈｔ３−受容体−アンタゴニストの使用 | |
| Hurd | CBD: Can it help people with opioid use disorder? |